Provided by Tiger Fintech (Singapore) Pte. Ltd.

Travere Therapeutics, Inc.

14.41
+0.32502.31%
Post-market: 13.93-0.4800-3.33%19:25 EDT
Volume:1.95M
Turnover:28.00M
Market Cap:1.28B
PE:-5.19
High:14.51
Open:14.06
Low:13.88
Close:14.09
Loading ...

Evercore ISI Sticks to Their Buy Rating for Travere Therapeutics (TVTX)

TIPRANKS
·
17 Jun

BRIEF-Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
13 Jun

Travere Therapeutics Announces Inducement Equity Grants to New Employees Under Nasdaq Rule

Reuters
·
13 Jun

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
13 Jun

Travere Therapeutics Is Maintained at Buy by Citigroup

Dow Jones
·
11 Jun

Travere Therapeutics Inc : H.c. Wainwright Assumes Coverage With Buy Rating; Price Target $30

THOMSON REUTERS
·
11 Jun

Travere Therapeutics Unveils Promising New Data on FILSPARI® for Rare Kidney Disease at International Podocyte Conference

Reuters
·
11 Jun

Travere Therapeutics Inc : Citigroup Cuts Target Price to $32 From $35

THOMSON REUTERS
·
11 Jun

Travere Therapeutics asumed with a Buy at H.C. Wainwright

TIPRANKS
·
11 Jun

Bank of America Securities Sticks to Their Buy Rating for Travere Therapeutics (TVTX)

TIPRANKS
·
10 Jun

Travere Therapeutics Inc. Announces Amendments to Equity Incentive Plan, Approved by Stockholders

Reuters
·
17 May

Travere Therapeutics Down Over 15%, on Pace for Largest Percent Decrease Since September 2023 -- Data Talk

Dow Jones
·
16 May

Scotiabank Sticks to Its Buy Rating for Travere Therapeutics (TVTX)

TIPRANKS
·
16 May

Travere Therapeutics' FDA Application Accepted for Filspari in Rare Kidney Disease

MT Newswires Live
·
16 May

Travere Therapeutics' FILSPARI sNDA for FSGS Treatment Accepted by FDA; PDUFA Target Date Set for January 2026

Reuters
·
16 May

BRIEF-Travere Therapeutics Announces FDA Acceptance Of SNDA For FILSPARI® (Sparsentan) In FSGS

Reuters
·
16 May

Travere Therapeutics Announces FDA Acceptance of Snda for Filspari® (Sparsentan) in Fsgs

THOMSON REUTERS
·
16 May

Travere Therapeutics Inc - Filspari Could Be First FDA-Approved Treatment for Fsgs

THOMSON REUTERS
·
16 May

Travere Therapeutics Inc - Pdufa Target Action Date Set for January 13, 2026

THOMSON REUTERS
·
16 May

Travere Therapeutics Announces Inducement Equity Grants for New Employees Under Nasdaq Rule 5635(c)(4)

Reuters
·
13 May